Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Dec 15, 2023 12:12pm
133 Views
Post# 35786886

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dr. Jean-Pierre Bizzari

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dr. Jean-Pierre Bizzari
Yes the science is good but so many small trials is hard for the end game.
CF, its not always about focusing on the negatives as you always give managment every break in the book no matter what and supporting every turn they make no matter what the cost. You supported the pp, you supported a tripling of managment compensation and even suggested that Matt had exercised his 350,000 options that he was just granted but what for the shareholders. My guess is that the stock was even walked down to allow this so they could make an excuse to not exercise their options that just expired even though they were in the money. I guess we will know on this one soon enough as it will have to be reported very soon whether they expired or were exercised.
Faith in someone or a company is one thing but blind faith with no oversight. Come on even you have to admit that the awarding of options was waaay out of line considering where the company stands right now and how can anyone be good with this as the company was asking for an increase of options but did not know if was just for them and their future.
Also as for a suggestion of taking the company private, Well no shareholders will every come out ahead on this and it would only be managment so not a good suggestion.

Now for the positives, Azzak made some good points as we have only really had good results so far with the company so now it is who is interested and what can we make of the results today going forward. Hopefully something is actually in the works but we will never know until it happens. My guess still is that with OS more than likely just around the corner that this will be what BP is waiting for to make their move with either a partnership or BO, Personally and IMO only , I think that a BO is in the best interest for BP as they are then in complete control with no stock manipulation or other entitities getting in the way.

so GLTA and hopefully something before the AGM at the latest.
<< Previous
Bullboard Posts
Next >>